key: cord-0971883-p5dain1c authors: Sethi, Sidharth Kumar; Rana, Abhyuday; Adnani, Harsha; McCulloch, Mignon; Alhasan, Khalid; Sultana, Azmeri; Safadi, Rama; Agrawal, Nirav; Raina, Rupesh title: Kidney Involvement in Multisystem Inflammatory Syndrome-C: A Pediatric Nephrologist’s Perspective date: 2021-04-15 journal: Clin Kidney J DOI: 10.1093/ckj/sfab073 sha: d403f484e15300df3d2fc23a8fb90d5d069d92ec doc_id: 971883 cord_uid: p5dain1c The initial report of the multisystem inflammatory syndrome (MIS-C) in children was from the United Kingdom in April 2020; since then, cases have been reported worldwide. Renal involvement has been seen commonly, ranging from 10% to 46%. Kidney involvement following SARS-CoV-2 infection in children with MIS-C is more common than initially thought and is associated with higher morbidity and mortality. There are several reports of a direct viral tropism of COVID-19 and MIS-C associated renal damage. This study's objective was to systematically review the current understanding of kidney involvement in children suffering from MIS-C. Based on our systemic literature search, 19 studies have either partially or fully discussed kidney involvement in MIS-C patients. Furthermore, we discuss the multifactorial pathogenesis contributing to AKI development in MIS-C. Conclusion: The current review gives a Pediatric Nephrologist's perspective of the renal involvement in MIS-C, the incidence of Acute Kidney Injury (AKI), the pathophysiology of AKI in MIS-C, and the proposed therapeutic regimens available, including the need for Kidney replacement therapy for a child with AKI associated with MIS-C. As the disease is rapidly evolving, more detailed clinical prospective studies are required to understand MIS-C and its role in AKI better. The case definitions made by the United States Center for Disease Control and Prevention (CDC) in association with the American Academy of Pediatrics (AAP), the World Health Organization (WHO), American College of Rheumatology (ACR), and Royal College of Pediatrics and Child Health (RCPCH) are summarized in (Table 1a, 1b, 1c, 1d) . The criteria used for case definition vary slightly between these agencies. The presence of fever remains common along all case definitions except a much broader duration of fever (>3 days) in WHO guidelines, in contrast to CDC, ACR and RCPCH. The CDC case definition adds several points that are unique to their guideline. Notably, severe illness requiring hospitalization for clinical symptoms and evidence of COVID-19 exposure within four weeks are important factors not present in other case definitions. While CDC and WHO case definitions require prior SARS-CoV-2 infection or exposure, RCPCH does not. These definitions are constantly evolving and likely to change as more updated information becomes available ( Table 2) . A systemic literature search was performed in PubMed/Medline from January 2020 to February 2021 to include all the studies related to MIS-C and Acute Kidney Injury. Medical subject headings (MeSH) terms including "Multisystem inflammatory syndrome", "pediatric inflammatory multisystem syndrome", "Kawasaki-like disease", "Acute kidney injury", "Acute renal injury", "renal dysfunction", were used in the search strategy. We excluded foreign language, and case reports during our analysis. Two independent reviewers assessed the literature based on the inclusion and exclusion criteria. A third independent reviewer evaluated articles with conflict. The studies were selected based on selecting any incidence of Acute kidney injury (AKI) or the use of renal replacement therapy in patients with MIS-C. A standardized data collection form was used to extract the following information from each included article: the last name of the first author, study type, location, number of MIS-C patients in the study, AKI incidence, use of renal replacement therapy. The initial search returned 91 studies; 18 studies met the selection criteria; 7 were multi-center studies; 8 were single-center studies, and 1 was a case series. Details of the included studies are provided in Table 3 . MIS-C presents with persistent fever > 38.5 o C, variable rash, conjunctivitis, peripheral edema, severe abdominal pain, and diarrhea. Fever is the most common presenting symptom, lasting for three to five days, though fewer days of fever have been reported [10] . Respiratory distress does not seem to be one of the main presenting symptoms of COVID-19, although a significant proportion of patients require respiratory support [8] . More significantly, many of these children present with hypotension and shock, requiring pressor support and pediatric ICU admission [6] . Echocardiogram findings include ventricular dysfunction and coronary artery abnormalities [17] . Patients with MIS-C also have evidence of severe inflammatory state, including elevation in C-reactive protein, ferritin, D-dimer, lactate dehydrogenase, pro-BNP and cardiac enzymes. Additionally, patients showed elevated pro-calcitonin levels, liver transaminases, anemia, along with thrombocytosis or thrombocytopenia ( The pathophysiology of MIS-C is still not well established. It's proposed that MIS-C occurs secondary to an abnormal immune reaction to the virus, much like KD and cytokine release syndrome (CRS) causing this disease [22] [23] . The mechanisms through which SARS-CoV-2 triggers the abnormal immune reaction are unknown. Unabated cytokine storm leading to endothelial dysfunction associated with SARS-CoV-2 infection has also been hypothesized [24] [25] . The mechanisms underlying the exaggerated immune reaction in MIS-C is a place of active investigation (Figure 1 ). Children tend to be less susceptible to severe respiratory infections than adults. The possible reason for a Milder reactions could be attributable to their robust innate immune response, healthier respiratory tracts, and few underlying illnesses. In addition to that, children are overprotected by their parents; many are involved in fewer outdoor activities and undertake less international travel. Notably, decreased gene expression of the ACE-2 receptor (the target of SARS-CoV-2) in the pediatric population could result in the age-related difference in the incidence of COVID-19 [26-29]. However, one of the major challenges is to understand the post-viral lag in symptom presentation in MIS-C patients. MIS-C cases predominantly occur four weeks post COVID-19 peak in the population pathology [35] . The pathogenesis of AKI in MIS-C is a complex, multifaceted entity with overlapping mechanisms. The means through which SARS-CoV-2 triggers the abnormal immune reaction are unknown. Investigators have reported several mechanisms for AKI in COVID-19. They are thought to occur secondary to an abnormal immune response to the virus leading to tubular injury and podocytopathy, inflammatory process, hemodynamic instability, and vascular endothelial dysfunction [23] . The underlying exaggerated immune reaction in MIS-C is a place of active investigation. COVID-19 exhibits viral tropism and can directly affect the kidney. The spike (S) glycoprotein of SARS-CoV-2 binds to the ACE2 receptor on host cells. Afterward, the active S protein is cleaved by transmembrane serine proteases (TMPRSSs), resulting in membrane fusion facilitated by fusion peptides released by the virus. Finally, the virus penetrates the proximal tubule cells and the podocytes leading to renal impairment (podocytopathy and tubular epithelial cell injury) [36] [37] . This is suggested by a coexpression of ACE2 and TMPRSS2 genes in the podocytes and proximal convoluted tubules, like that in the lung, small intestine, and colon [37] . Sub-saharan African descent with high-risk APOL1 genotype (presence of 2 risk alleles) could be at increased risk of kidney disease in the setting of COVID-19 [38] . Case reports of patients presenting with heavy proteinuria associated with collapsing glomerulopathy with a predisposition in the form of apolipoprotein-1 (APOL-1) polymorphism suggest a crucial role of innate immunity pathways, which are upregulated in viral illnesses [39] . The development of a hyperinflammatory state as a response to the virus in MIS-C suggests a macrophage activating syndrome (MAS) like cytokine storm or secondary hemophagocytic lymphohistiocytosis (HLH). MAS or secondary HLH is a life-threatening condition triggered by an autoimmune condition or viral illness [40] . The findings indicative of MAS includes cytopenias, coagulopathy, tissue damage, and hyperferritinemia leading to a fatal multi-organ failure [23, [41] [42] . Similar findings have been noticed in MIS-C patients, specifically hyperferritinemia on admission, associated with severe AKI contributing to the acute inflammatory state in MIS-C [43] . Furthermore, data from an adult study on secondary HLH demonstrates increased AKI incidence adversely affecting patient survival [44] . IL-6 plays a crucial role in inducing the systemic inflammatory response in COVID-19, and elevated levels have been associated with worsening renal outcomes [47] [48] . A positive correlation was shown between severity of COVID-19 disease and serum levels of IL-6 and IL-2 receptor (IL-2R) [49] . Interestingly, experimental studies demonstrate a role of IL-6 activation and secretion by podocytes, endothelial cells, mesangial cells, and tubular epithelial cells in renal inflammatory diseases. IL-6 levels would therefore aid in early diagnosis, serve as a target for therapeutics, and prevent AKI worsening [50] [51] . Similarly, a proinflammatory cytokine, IL-8, plays a role in recruiting neutrophils and lymphocytes in the tubular interstitium causing inflammation. Investigational studies demonstrate upregulation of IL-8 in tubular epithelial cells due to elevated albumin and proteinuria leading to AKI [52] . A study on adults reported that 34% of COVID-19 infected individuals acquired proteinuria on the first day of admission, with 63% presenting with proteinuria during their hospital stay [53] Proteinuria of any degree is associated with poor prognosis and increased in-hospital mortality [54] . In conclusion, it is plausible to hypothesize that these cumulative mechanisms could propel renal function impairment in a hypercytokinemia state of MIS-C. The pathogenesis of post-viral inflammatory response of MIS-C raises the concern for cytokinemediated hypotension leading to renal hypoperfusion associated with AKI [9]. Deep et al. [43] conducted a multicenter study on 116 PIMS-TS patients, demonstrating 41.4% of children with AKI (any stage) and 27.6% with severe AKI. Nearly half (49%) patients presented with vasodilatory shock requiring vasopressor support. In the same way, Stewart et al. observes the interaction between hypervolemia and hyper inflammatory shock in majority of their patients with AKI. The renal function improved following fluid resuscitation and use of inotropic support. However, the study was focused on pediatric patients with COVID-19 who suffered renal dysfunction [55] . Other factors, including vomiting and diarrhea, also precipitated dehydration leading to inadequate renal perfusion. These could be contributing to decreasing effective renal perfusion, thereby supporting renal hypoperfusion as a factor causing AKI [56] [57] (Figure 2 ). Other etiologies that may contribute to AKI development in MISC patients include: 1. Imbalanced renin-angiotensin-aldosterone system activation promoting glomerular dysfunction, fibrosis, vasoconstriction [58] . 2. Endothelial dysfunction, complement, and coagulation activation, leading to kidney vascular injuries such as ischemic glomeruli and fibrinoid necrosis [39] . 3. Obstruction of the glomerular capillaries by red blood cells similar to the case in thrombotic microangiopathy [59] . 4 . Drug toxicity and organ cross-talks are non-specific factors relative to critically ill COVID-19 patients management that may aggravate kidney injury [59] [60] [61] . corticosteroids as primary therapy (98% and 93%, respectively). Additionally, heparin, anakinra, and vasopressor agents were used frequently in children with severe illness [62] . The primary goal of the therapy in MIS-C is to reduce systemic inflammation with organ restoration decreasing mortality and reducing the risk of long-term sequelae. There is a need for multispecialty care guiding management and rehabilitation in patients with MIS-C due to its varied nature and presentation. The suitable care setting is determined by the severity of the disease, risk of complications, and followup ability. Children with mild symptoms, normal vital signs, and physical examination can be managed in the outpatient setting with appropriate follow-up. Children with moderate to severe symptomatic MIS-C (Table 4) General supportive care is pivotal in management. [9] The focus should be placed on the patient's vital signs, hydration status, electrolytes, and metabolic status. Special care in early detection of signs of hypoxia with prompt intervention should be taken for better outcomes. Children presenting with shock should be resuscitated according to standard protocols, with early goal-directed volume expansion followed by vasoactive agents [65] . In the event of LV dysfunction, epinephrine is preferable, with the addition of milrinone in case of severe LV dysfunction [65] . Children meeting the criteria for KD should receive standard therapies, including intravenous immunoglobulin (IVIG), aspirin, and, if facing persistent signs of inflammation or coronary artery dilation/aneurysm, glucocorticoids. In instances of fulminant disease, mechanical hemodynamic support could also be necessary within the sort of extracorporeal membrane oxygenation (ECMO) or a ventricular assist device [41] . IVIG 2 g/kg and aspirin 20-25 mg/kg/dose every six hours (80-100 mg/kg/day) should be used for all patients with KD-like illness, evidence of excessive inflammation (ferritin >700 ng/mL, CRP >30 g/dL, or multisystem organ failure), or cardiac involvement. Aspirin dosage may also vary at individual centers. IVIG 2 g/kg as a single infusion with three-day pulse methylprednisolone should be reserved for patients in high-risk categories (infants, KD shock syndrome, CRP >130 g/dL, admission echo Z score >2.5 or aneurysms, Asian race) [41] . Patients with persistent inflammation despite IVIG and steroids can be given Anakinra, an IL-1 receptor antagonist, Tocilizumab, an IL-6 antagonist and Infliximab, TNFalpha blocker. Until now, the data on IL-1 and IL-6 blockade in COVID-19 infection and associated MISC is limited but encouraging, with multiple clinical trials currently in progress showing a high shortterm survival rate in patients receiving IVIG and steroids [50] [51] 66] (Table 5) . KRT in the setting of multiorgan disease syndrome (MODS) should be instituted with expertise. KRT can be utilized non-selectively to clear inflammatory mediators via convection, adsorption, and diffusion. Continuous Kidney Replacement Therapy (CKRT) corrects fluid overload and manages solute levels to provide hemodynamic stability in catabolic pediatric patients [67] . Immediate initiation of preemptive KRT in cases with progressive symptomatic respiratory insufficiency improves overall outcomes. The Pediatric Continuous Renal Replacement Therapy (PCRRT) group advises the early initiation of KRT in critically ill COVID-19 related immune dysregulation syndrome patients since it has been shown to mitigate fluid overload, enhance cytokine clearance, improve PaO 2 /FiO 2 ratios, and establish hemodynamic stability earlier, leading to better overall outcomes [68] . No additional benefit has been reported with hybrid therapies such as prolonged intermittent renal replacement therapy (PIRRT) and sustained low efficiency dialysis (SLED). Hence, it is suggested to continue using the local institution's recommended treatment modality. If CKRT/PIRRT is not available, intermittent hemodialysis is acceptable [68] . In terms of CKRT modality, the use of high flow continuous venovenous hemodiafiltration (HF-CVVHDF) in critically ill COVID-19 pediatric patients is recommended because of its ability to boost the non-specific removal of the circulatory cytokine mediators [69] . Increased reports of thrombotic complications are coming up in patients with MIS-C. Care should be taken during dialysis to avoid circuit clotting. As per local protocols, after insertion with heparin/citrate, the catheter's immediate locking may be considered [70] . Some critically ill patients require mechanical ventilation via ECMO. Integration of the ECMO circuit with the CKRT equipment for these patients can provide additional respiratory support while reducing/preventing fluid overload and cytokine clearance [68] . However, the use of ECMO comes with a risk of potentially accentuating the cytokine activation. Although there has been an increasing number of published data, the overall population-specific d. Contact with an individual with COVID-19 World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief. 2020. Available at: https://www.who.int/publications-detail/multisysteminflammatory-syndrome-in-children-and-adolescents-with-covid-19 (Accessed on May 17, 2020) BNP, brain natriuretic peptide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription-polymerase chain reaction; COVID-19, coronavirus disease 2019 5)Hypoalbuminemia 5. SARS-CoV-2 PCR and/or serologies 6. Exclusion of other infections GI, Gastrointestinal; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; ALC, Absolute lymphocyte count; Na, Sodium; SARS-CoV-2 PCR, severe acute respiratory syndrome coronavirus 2 polymerase chain reaction 1) Single or multi-organ dysfunction AND 3. Clinical Symptoms 2) Additional features* 1) Neutrophilia 2) Increase CRP AND 4. Laboratory evidence**: 3)Lymphopenia 5. SARS-CoV-2 PCR and/or serologies 6. Exclusion of other infections *Abdominal pain, Confusion, Conjunctivitis, Cough, Diarrhea, Headache, Lymphadenopathy, Mucus membrane changes, Neck swelling, Rash, Resp symptoms, Sore throat, Swollen hands and feet, Syncope, Vomiting **High D-Dimers, High ferritin, Hypoalbuminemia CRP, C-reactive protein; SARS-CoV-2 PCR, severe acute respiratory syndrome coronavirus 2 polymerase chain reaction WHO coronavirus disease (COVID-19) dashboard. World Health Organization Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis Children with Covid-19 in pediatric emergency departments in Italy Novel coronavirus infection in hospitalized infants under 1 year of age in China Hyperinflammatory shock in children during COVID-19 pandemic SARS-CoV-2-Induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational cohort study Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children Multisystem inflammatory syndrome in children in New York State Pediatric Critical Care and COVID-19 COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic Antibodydependent enhancement of severe disease is mediated by serum viral load in pediatric Dengue virus infections Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies Multiorgan and renal tropism of SARS-CoV-2 Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis Collapsing Glomerulopathy in a Patient With COVID-19 Collapsing Glomerulopathy in a Patient With COVID-19 Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management COVID-19 associated Multisystem Progress in pediatric cardiology, 101232. Advance online publication On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis & rheumatology Acute Kidney Injury in Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic: Experience From PICUs Across United Kingdom Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. American journal of kidney diseases : the official journal of the National Kidney Foundation Similarities and differences between the immunopathogenesis of COVID-19-related pediatric inflammatory multisystem syndrome and Kawasaki disease SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update Plasma cytokine levels predict mortality in patients with acute renal failure Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases Tocilizumab treatment in COVID-19: A single center experience Effective treatment of severe COVID-19 patients with tocilizumab Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo Caution on Kidney Dysfunctions of 2019-nCoV Patients Kidney disease is associated with in-hospital death of patients with COVID-19 Renal dysfunction in hospitalized children with COVID-19 Acute Kidney Injury in Multisystem Inflammatory Syndrome in Children (MIS-C): a Case Report Peritoneal dialysis for treatment of acute kidney injury in a case of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis Reninangiotensin-aldosterone system inhibitors in patients with Covid-19 Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China COVID-19 therapeutic options for patients with kidney disease Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. The Lancet Child & Adolescent Health Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with COVID-19 in New York City Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls Induced Kidney Failure and Septic Shock: A Pediatric Continuous Renal Replacement Therapy [PCRRT] Position on Emergency Preparedness With Resource Allocation Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 Severe Coronavirus Disease-2019 in Children and Young Adults in the Atrioventricular Block in Children With Multisystem Inflammatory Syndrome Moderate to severe signs and symptoms of MIS-C 1. Abnormal vital signs (tachycardia, tachypnea) Evidence of cardiac involvement (e.g., elevated troponin or BNP, depressed ventricular function or CA abnormality on echocardiogram Neurologic changes (e.g., depressed mental status, abnormal neurologic examination, seizures) Underlying medical conditions that may place the child at increased risk for complications Angiotensin Aldosterone System; ACE-I, Angiotensin converting enzyme-I ACE-II, Angiotensin converting enzyme-II; ACE-IR, Angiotensin converting enzyme-I receptor SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ACE-IIR, Angiotensin converting enzyme-II receptor; NK cell Interferon-gamma; TNF-α, Tumor necrosis factor-alpha Acute Kidney Injury Short term outcomes of AKI in PIMST appears good, long-term outcomes are unknown SD, standard deviation; AKI, acute kidney injury; KRT, kidney replacement therapy; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; IVIG, intravenous immunoglobulin; PICU, pediatric intensive care unit; RT-PCR, reverse transcription-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.